Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNT0003 with Imlifidase in Crigler-Najjar Syndrome
NCT06518005Phase 2Recruiting
- Sponsor
- Généthon
- Start
- Nov 2024
- Primary completion
- Sep 2026
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of GNT-0003 in Crigler-Najjar syndrome (CNS), sponsored by Généthon. Started Nov 2024; status: recruiting.
02
Drugs
GNT-0003
03
Conditions
Crigler-Najjar syndrome (CNS)
Beyond the preview
Go deeper on NCT06518005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06518005.